GLP-1 Receptor Agonists and Neurodegeneration Research
Brain receptors built for blood sugar control may slow Alzheimer's and Parkinson's decline.
Séverine Okafor
Staff Writer, Neuropharmacology
Séverine Okafor
Séverine Okafor trained as a pharmacologist in Lyon and later completed a postdoctoral fellowship studying blood-brain barrier transport mechanisms before leaving the bench in 2019 to write full-time. Her coverage focuses on CNS-targeted therapies and the translational gap between animal models and human outcomes.
3 stories
Absolute Bioavailability of Intranasal Peptide Formulations
Four variables govern how much intranasal peptide reaches your bloodstream.
Séverine Okafor
Proteolytic Barriers at the Nasal Mucosa for Peptide Therapeutics
Enzymes in the nasal lining degrade peptides before they reach circulation or the brain.
Séverine Okafor